NCT04884685 is a Phase 2 clinical trial of SARS-CoV-2 Inactivated Vaccine in COVID-19, sponsored by Sinovac Life Sciences Co., Ltd..

Who is sponsoring NCT04884685?

NCT04884685 is sponsored by Sinovac Life Sciences Co., Ltd..

What drugs are being tested in NCT04884685?

Interventions in NCT04884685: SARS-CoV-2 Inactivated Vaccine, Placebo.

Is NCT04884685 still recruiting?

NCT04884685 is currently completed. Last updated 22 September 2023.

Last reviewed 2023-09-22 · How we verify

NCT04884685

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents

Completed Phase 2 Last updated 22 September 2023

What this trial tests

Phase 2 trial testing SARS-CoV-2 Inactivated Vaccine in COVID-19 in 500 participants. Completed in 20 June 2022.

Timeline

3 May 2021

Primary endpoint
1 August 2021

20 June 2022

Quick facts

Lead sponsor	Sinovac Life Sciences Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	500
Start date	3 May 2021
Primary completion	1 August 2021
Estimated completion	20 June 2022
Sites	1 location across China

Drugs / interventions tested

SARS-CoV-2 Inactivated Vaccine — full drug profile →
Placebo

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Sinovac Life Sciences Co., Ltd. — full company profile →

Who can join

Adults 3 to 17, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a randomized, double-blinded, placebo-controlled, phase Ⅱb clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Life Sciences Co. , Ltd.The purpose of this study is to evaluate the safety of the SARS-CoV-2 Inactivated vaccine in healthy children and adolescents aged 3-17 years.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy and safety of COVID-19 vaccines.
Graña C, Ghosn L, Evrenoglou T, Jarde A, et al · · 2022 · cited 227× · PMID 36473651 · DOI 10.1002/14651858.cd015477
COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety.
Luxi N, Giovanazzi A, Capuano A, Crisafulli S, et al · · 2021 · cited 98× · PMID 34739716 · DOI 10.1007/s40264-021-01131-6
Safety and efficacy of COVID-19 vaccines in children and adolescents: A systematic review of randomized controlled trials.
Tian F, Yang R, Chen Z. · · 2022 · cited 47× · PMID 35705969 · DOI 10.1002/jmv.27940
COVID-19: Clinical status of vaccine development to date.
Kumar S, Basu M, Ghosh P, Ansari A, et al · · 2023 · cited 17× · PMID 36184710 · DOI 10.1111/bcp.15552
Multi-omics for COVID-19: driving development of therapeutics and vaccines.
Guo M, Xiong M, Peng J, Guan T, et al · · 2023 · cited 14× · PMID 37936830 · DOI 10.1093/nsr/nwad161
COVID-19 vaccination in pediatric cancer patients: A high priority.
Charla Y, Kalra M, Chopra N, Choudhury S. · · 2021 · cited 8× · PMID 34636133 · DOI 10.1002/pbc.29397

Verify or expand the search:

Other trials of SARS-CoV-2 Inactivated Vaccine

Trials testing the same drug.

NCT05067894 — Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine · Phase 1 · completed
NCT04962308 — Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults · Phase 4 · unknown

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Sinovac Life Sciences Co., Ltd. trials

Trials by the same sponsor.

NCT07374510 — Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine · Phase 1 · not yet recruiting
NCT06967272 — PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) · Phase 2 · recruiting
NCT06617715 — Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine · Phase 3 · recruiting
NCT06550830 — Clinical Trial of PCV24 in Children Aged 2-17 Years · Phase 1 · completed
NCT06474377 — Clinical Trial of PCV24 in Adults · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04884685 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sinovac Life Sciences Co., Ltd.
Last refreshed: 22 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04884685.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing